Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PBH with free AI briefings, catalyst countdowns, and dilution alerts.

PBH · Prestige Consumer Healthcare Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$46.5M Cash on Hand
CF+ Cash Runway
Follow PBH by email Get an email when PBH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PBH, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Epirubicin HER2 Positive Breast Cancer Phase 3 · NCT03013504 Completed
PBP1510 (400mg/16mL) Pancreatic Cancer Phase 1/2 · NCT05141149 Active not recruiting

Also used in these trials (approved or third-party drugs, not PBH's own candidates): Bevacizumab (HD204), Carboplatin, Cyclophosphamide, Docetaxel Anhydrous, Trastuzumab, Paclitaxel, Gemcitabine Hydrochloride, Adalimumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PBH holds $46.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PBH files for a raise →

👥 Who Owns PBH

Insiders 1.5% Institutions (454 holders) 98.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
Ariel Investments, LLC Institution (13G, 5%+) 4,868,711 10.27% 2026-06-30
Vanguard Portfolio Management Institution (13G, 5%+) 2,826,536 5.96% 2026-03-31
FULLER & THALER ASSET MANAGEMENT, INC. Institution (13G, 5%+) 2,527,139 5.33% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 2,454,974 5.18% 2026-03-31
Ronald M. Lombardi
Chief Executive Officer, Director
Insider 373,465 0.79% 2026-05-07
Christine Sacco
CFO & COO
Insider 71,636 0.15% 2026-05-07
John E Byom
Director
Insider 54,575 0.12% 2026-08-04
Jeffrey Zerillo
Senior VP Operations
Insider 41,810 0.09% 2026-05-11
Sheila Hopkins
Director
Insider 30,123 0.06% 2025-08-05
William P'Pool
SVP, General Counsel & Corp Secretary
Insider 28,249 0.06% 2026-05-04
Adel Mekhail
EVP, Marketing & Sales
Insider 25,703 0.05% 2026-05-07
Dawn M. Zier
Director
Insider 19,514 0.04% 2026-08-04

Share count 47,397,106 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PBH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PBH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.